Back to Journals » Journal of Asthma and Allergy » Volume 3

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated

Authors Kariyawasam HH, Scadding G 

Published 21 June 2010 Volume 2010:3 Pages 17—26

DOI https://doi.org/10.2147/JAA.S6698

Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Harsha H Kariyawasam, Glenis K Scadding

Royal National Throat Nose and Ear Hospital and Royal Free Hospital NHS Trust University College London, UK

Abstract: Seasonal allergic rhinitis (SAR) is increasing in prevalence such that 1 in 4 persons is affected in the UK. It represents a considerable burden of disease since in a significant proportion of individuals the severity of nasal–ocular symptoms has an important effect on daily activity, performance and quality of life. Intranasal steroids (INS) form the mainstay of treatment, having been shown in meta-analyses to be superior to oral antihistamines, intranasal antihistamines and anti-leukotrienes. Fluticasone propionate is an established INS for the treatment of rhinitis, including SAR. Its favorable pharmacological profile combining high local efficacy with low systemic bioavailability has established fluticasone propionate as an effective intervention. The more recent introduction of structurally related fluticasone furoate with similar but enhanced pharmacological characteristics with a novel delivery device may confer further therapeutic advantages.

Keywords: seasonal allergic rhinitis, fluticasone furoate, fluticasone propionate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]